Exelixis (EXEL) Commences Phase 3 of Cabozantinib vs. Everolimus in MRCC ... StreetInsider.com (subscription) Exelixis, Inc. (Nasdaq: EXEL) has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma (mRCC) who have experienced disease progression following treatment with at least one ... Exelixis Initiates Phase 3 Pivotal Trial of Cabozantinib in Patients With ... |
